Anthropic Announced New Achievements in Drug Research and Lab Work. An Expert Says AI is ‘Changing the Medical Field.’

Anthropic is expanding into biotechnology through drug-development partnerships, its own biology laboratory, and the acquisition of a company researching rare muscular diseases, bringing the artificial intelligence company deeper into the search for new medicines.

In a new announcement, Anthropic outlined collaborations with six organizations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences. The company plans to expand research that puts Claude to work across scientific and operational stages of drug development.

The expansion builds on an internal life sciences research group formed in spring 2026. Anthropic disclosed its molecular biology laboratory in September, describing an approach that combines AI analysis of biological data with experiments conducted by human scientists.

Anthropic's October 26 initial public offering filing outlined further investment in life sciences expertise, partnerships and acquisitions. The filing confirmed its purchase of Coefficient Bio, an AI biotechnology startup. Dr. Michael Riddle, a physician and inventor who leads biotechnology company Mesogen, said AI's growing role in medicine, however, requires continued human supervision.

"AI is changing the medical field by making it easier to analyze large amounts of data, improve diagnostics, support more personalized treatment, and speed up research and decision-making overall. In biotech AI is making R&D and biological data analysis faster, but regenerative medicine still requires strong human oversight and validation from doctors," Riddle said.

One Anthropic collaboration illustrates how AI can contribute to experimental design. Generate Biomedicines researchers worked with AI agents to increase "the usefulness of a cancer treatment known as CAR T-cell therapy. This therapy has historically helped treat blood cell cancers; Generate aims to reengineer it so that it can treat solid tumor cancers too."

"Six Generate scientists used Claude Code to propose new designs for this part. One design was about 70% shorter than the standard version, and in lab tests it was more effective: it allowed immune cells to make roughly 10 times as many receptors (the proteins they use to spot cancer cells), it killed tumor cells more efficiently, and the immune cells remained active for longer," the company said.

Other applications address documentation surrounding drug manufacturing. Enveda developed a language-model system to review completed pharmaceutical batch records. The system examines production documentation, a separate task from determining whether a drug works.

Anthropic is also developing potential medicines directly. It acquired Mithril Medicine, whose founder used Claude to coordinate external laboratory work on rare forms of muscular dystrophy. Anthropic reported promising mouse results and said human trials could begin as early as late 2028 if development remains successful.

In September, Anthropic reported that Claude had identified an unusual enzyme system associated with repeating DNA sequences. The company said the system had features reminiscent of CRISPR, but its function remained unknown.

Human scientists performed laboratory experiments, and further investigation was underway. The finding did not establish a new gene-editing treatment. Commercial adoption is also growing. Anthropic's IPO filing said nine of the world's 10 largest pharmaceutical companies were customers as of September 30, although it did not identify them.